Monday, March 14, 2016
INC Research, a, global phase I to IV CRO, has appointed Judith Ng-Cashin, M.D., as chief scientific officer. Dr. Ng-Cashin will lead the integration of the Company’s industry-recognized therapeutic and medical/scientific expertise for phase I to IV clinical trials. She will be responsible for scientific, medical and ethical governance matters, including collaboration with key medical and scientific stakeholders to strengthen INC’s position as a collaborative partner to clinical practice, sponsor and academic organizations.
Greenphire, a global clinical payment solutions provider, has appointed Wayne Baker as chief commercial officer to lead the commercial strategy of the rapidly growing organization worldwide. Wayne brings more than 25 years of global commercial experience in technology and life science industries, most recently serving as the senior vice president and chief sales officer at Advanced Health Media (AHM).
The Pulse on Global Trials by Matthew Howes
Most industry experts estimate that supply chain logistics for clinical trials account for 20 to 25% of total R&D costs. There is evidence that those estimates are growing. EvaluatePharma reports that logistics services are experiencing a growth rate of 12%, which is faster than the more stable overall market growth of 2 to 2.5%. With rising cost pressures from payers and policy makers worldwide, it is surprising that more attention has not been paid to this increasingly dominant factor in clinical development.
Clintrax Global has joined the WIRB-Copernicus Group (WCG) family of companies. WCG is a leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced that. Founded by former biopharmaceutical and CRO attorneys, Clintrax Global provides outsourced services for negotiating clinical trial-related contracts and budgets between biopharmaceutical companies, CROs and investigator sites around the world. Clintrax Global also manages, executes, and tracks payments between these global clinical trial participants.
Investments in research and development for new immuno-oncology (I/O) drugs, along with dramatic improvements in complete response rates in trials for new I/O therapies, are helping to increase the number of alliances between pharmaceutical and biotech companies and university and cancer centers, a new analysis by the Tufts Center for the Study of Drug Development shows (CSDD).
Prexton Therapeutics, a biopharmaceutical company developing novel therapeutics for the treatment of CNS conditions, has launched a phase I clinical trial. Prexton Therapeutics is the first company to enter in man clinical trials with an mGluR4 positive allosteric modulator. The trial should be complete by mid 2016, with results expected in August 2016.
Vaxart, a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, has initiated preclinical testing of an oral vaccine for Zika virus. With no available vaccine or treatment modalities, the World Health Organization (WHO) recently declared Zika virus an international public health emergency.